Canaccord analyst William Plovanic raised the firm’s price target on DexCom to $144 from $140 and keeps a Buy rating on the shares. The firm believes the company is set up for success in 2024 as management painted conservative guidance with a strong pipeline worth watching.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DXCM:
- DXCM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- DexCom price target raised to $140 from $137 at Canaccord
- DexCom breaks ground on new manufacturing facility in Ireland
- DexCom price target raised to $145 from $136 at Wells Fargo
- DexCom sees FY24 revenue $4.15B-$4.35B, consensus $4.32B
